Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infection.
Zhao X, Feng J, Zhang J, Han Z, Hu Y, Shao HH, Li T, Xia J, Lei K, Wang W, Lai F, Lin Y, Liu B, Zhang K, Zhang C, Yang Q, Luo X, Zhang H, Li C, Zhang W, Wu S.
Zhao X, et al. Among authors: zhang c, zhang w, zhang j, zhang k, zhang h.
Acta Pharm Sin B. 2023 Dec;13(12):4945-4962. doi: 10.1016/j.apsb.2023.08.030. Epub 2023 Sep 9.
Acta Pharm Sin B. 2023.
PMID: 38045053
Free PMC article.